Cancer Cell Patents (Class 424/155.1)
-
Patent number: 7582736Abstract: This invention provides novel prostate cancer specific internalizing human antibodies. The antibodies are useful by themselves to prevent growth and/or proliferation of prostate cancer cells. The antibodies can also be formulated as chimeric molecules to direct an effector (e.g. a cytotoxin, an imaging reagent, a drug, etc.) to a prostate tumor site.Type: GrantFiled: January 10, 2008Date of Patent: September 1, 2009Assignee: The Regents of the University of CaliforniaInventors: Bin Liu, James D. Marks
-
Publication number: 20090208411Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB) or derivatives thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMABs of the instant invention.Type: ApplicationFiled: February 13, 2009Publication date: August 20, 2009Inventors: David S.F. Young, Susan E. Hahn, Helen P. Findlay
-
Publication number: 20090205056Abstract: Detection of expression of the provided protein kinase in cancers is useful as a diagnostic, for determining the effectiveness of drugs, and determining patient prognosis. The encoded polypeptides further provides a target for screening pharmaceutical agents effective in inhibiting the growth or metastasis of tumor cells.Type: ApplicationFiled: January 14, 2008Publication date: August 13, 2009Inventors: Allen Delaney, Thillainathan Yoganathan
-
Publication number: 20090202560Abstract: The invention concerns methods and compositions for intiating and/or enhancing an immune response by contacting a binding reagent with a soluble antigen, wherein the binding reagent-antigen pair generates an immune response to the antigen.Type: ApplicationFiled: October 31, 2007Publication date: August 13, 2009Applicant: AltaRex Medical Corp.Inventors: Ragupathy Madiyalakan, Antoine A. Noujaim, Richard P. Baum, Bruce Darryl Hirsche
-
Patent number: 7572444Abstract: Binding proteins, such as fully human monoclonal antibodies and fragments thereof, directed to the antigen Matriptase and uses of such binding proteins are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising heavy and light chain immunoglobulin molecules capable of binding to Matriptase are also disclosed. The invention also discloses cell lines expressing such immunoglobulin molecules and monoclonal antibodies to Matriptase. The antibodies can be used to detect, prevent, and treat diseases such as cancer.Type: GrantFiled: December 16, 2005Date of Patent: August 11, 2009Assignees: Amgen Fremont Inc., Dendreon CorporationInventors: Ian Foltz, Chadwick King, Peter Koon Bong Ling, Jaspal Singh Kang, Kathy Manchulenko, Francine Chen, Caroline Darne Scatena, Bruce A. Keyt, Edwin Madison, Wayne R. Godfrey, Stanislaw K. Morkowski, Jennifer H. Richardson
-
Patent number: 7572442Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.Type: GrantFiled: July 15, 2003Date of Patent: August 11, 2009Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Sophia Ran
-
Patent number: 7572448Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.Type: GrantFiled: August 15, 2003Date of Patent: August 11, 2009Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Xianming Huang, Sophia Ran
-
Patent number: 7569674Abstract: Antibodies having noncovalent, autophilic properties are disclosed. The autophilic antibodies are derived from antibodies conjugated with an autophilic peptide. Such autophilic antibodies can promote apoptosis of target cells and enhance therapeutic efficacies in the treatment of patients with diseases or disorders responsive to antibody therapy. Compositions containing the antibodies, and methods of making and using the antibodies are also disclosed.Type: GrantFiled: April 29, 2005Date of Patent: August 4, 2009Assignee: InNexus Biotechnology International LimitedInventors: Heinz Kohler, Sybille Muller
-
Patent number: 7569673Abstract: The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody in the detection or treatment of a tumor in a subject. Also disclosed is a kit including the humanized CC49 antibody described herein.Type: GrantFiled: June 26, 2003Date of Patent: August 4, 2009Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Syed V. S. Kashmiri, Jeffrey Schlom, Eduardo A. Padlan
-
Publication number: 20090191118Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: ApplicationFiled: August 20, 2008Publication date: July 30, 2009Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Luis A. G. DaCruz, Alison L. Ferry
-
Publication number: 20090191120Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: ApplicationFiled: January 21, 2009Publication date: July 30, 2009Inventors: David S.F. Young, Helen P. Findlay, Susan E. Hahn, Lisa A. Popp
-
Patent number: 7563882Abstract: The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene.Type: GrantFiled: June 10, 2003Date of Patent: July 21, 2009Assignee: University of RochesterInventors: Maurice Zauderer, Elizabeth E. Evans
-
Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer
Patent number: 7563444Abstract: A novel gene (designated 213P1F11) and its encoded protein, and variants thereof, are described wherein 213P1F11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 213P1F11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 213P1F11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 213P1F11 can be used in active or passive immunization.Type: GrantFiled: March 25, 2005Date of Patent: July 21, 2009Assignee: Agensys, Inc.Inventors: Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits -
Patent number: 7563439Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The antigenic linker is conjugated to one or more therapeutic or diagnostic agents or enzymes. In one embodiment, the invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them.Type: GrantFiled: October 24, 2007Date of Patent: July 21, 2009Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Gary L. Griffiths, Shui-on Leung, William J. McBride, Zhengxing Qu
-
Publication number: 20090181034Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.Type: ApplicationFiled: March 4, 2009Publication date: July 16, 2009Inventors: Jean GUDAS, Aya Jakobovits, Xiao-Chi Jia, Robert Kendall Morrison, Karen Jene Meyrick Morrison, Hui Shao, Pia M. Challita-Eid, Arthur B. Raitano
-
Patent number: 7560095Abstract: Novel monoclonal antibodies and binding fragments thereof specific to human breast cancer, lung cancer, colon cancer and other cancers. The monoclonal antibody does not bind to the cell surface of normal human tissues. The corresponding cancer-specific antigen or antigens with an apparent molecular weight of 40-52 130-200 kDa and polynucleotides encoding the antigen and the CDR regions of the antibody are also disclosed, as well as methods for diagnosis, prognosis and treatment of human breast cancer. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of cancers. The antibody-recognized cancer-specific surface antigens can serve as targets for detecting, diagnosing, inhibiting or killing cancer cells.Type: GrantFiled: April 22, 2004Date of Patent: July 14, 2009Assignee: A & G Pharmaceutical, Inc.Inventors: Le Sun, Ginette Serrero, Joe Corvera, Yudong Hou
-
Patent number: 7557189Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.Type: GrantFiled: November 5, 2003Date of Patent: July 7, 2009Assignee: Immunogen Inc.Inventors: Mary G. Hoffee, Daniel Tavares, Robert J. Lutz
-
Patent number: 7556803Abstract: The present invention relates to methods for the treatment of multiple myeloma. More particularly, the present invention relates to a method for inducing apoptosis in myeloma cells by administration of a K121-like antibody.Type: GrantFiled: January 18, 2008Date of Patent: July 7, 2009Assignee: Immune System Therapeutics LtdInventors: Robert Lindsay Raison, Rosanne Dorothy Dunn, Boon Hwa Andre Choo
-
Patent number: 7550568Abstract: The present invention provides monoclonal antibodies that react against high molecular weight melanoma-associated antigen. These antibodies may be used for diagnostic and/or therapeutic purposes.Type: GrantFiled: February 28, 2008Date of Patent: June 23, 2009Assignee: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventor: Soldano Ferrone
-
Patent number: 7550142Abstract: The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: November 13, 2006Date of Patent: June 23, 2009Assignee: Centocor, Inc.Inventors: Jill Giles-Komar, Linda Snyder, Mohit Trikha, Marian T. Nakada
-
Publication number: 20090155262Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.Type: ApplicationFiled: September 18, 2008Publication date: June 18, 2009Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Luis A. G. da Cruz, Daad Sayegh, Kristian Rogers, Shankar Kumar, Paul Hinton
-
Patent number: 7547768Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: November 20, 2007Date of Patent: June 16, 2009Assignee: Genentech, Inc.Inventors: Patrick Dowd, Gretchen Frantz, Paul Polakis, Victoria Smith, Susan D. Spencer, Thomas D. Wu, Zemin Zhang
-
Patent number: 7544358Abstract: Methods and compositions comprising antagonists of ?v?6 are provided for the treatment of acute lung injury fibrosis.Type: GrantFiled: November 13, 2006Date of Patent: June 9, 2009Assignee: The Regents of the University of CaliforniaInventors: Xiaozhu Huang, Dean Sheppard, Robert Pytela
-
Patent number: 7541044Abstract: The invention provides the use of an enzyme and a prodrug in the manufacture of a medicament for use in inducing an anti-tumor immune response in a human patient.Type: GrantFiled: September 29, 2006Date of Patent: June 2, 2009Assignee: Oxford Biomedica (UK) LimitedInventors: Richard Harrop, Miles Carroll, Susan Kingsman
-
Patent number: 7538195Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.Type: GrantFiled: June 14, 2002Date of Patent: May 26, 2009Assignee: Immunogen Inc.Inventors: Rajeeva Singh, Daniel J. Tavares, Nancy E. Dagdigian
-
Publication number: 20090130101Abstract: Methods of treating cancer with a combination of an extract of Scutellaria barbata D. Don and at least one additional anticancer chemotherapeutic agent are provided. Also provided are kits comprising an extract of Scutellaria barbata D. Don and at least one additional anticancer chemotherapeutic agent.Type: ApplicationFiled: November 19, 2008Publication date: May 21, 2009Applicant: BIONOVO, INC.Inventor: Isaac Cohen
-
Patent number: 7534431Abstract: Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.Type: GrantFiled: February 2, 2004Date of Patent: May 19, 2009Assignee: Immunomedics, Inc.Inventors: William J. McBride, Hans J. Hansen, Chien-Hsing Ken Chang, David M. Goldenberg
-
Publication number: 20090117034Abstract: Modified viruses encoding transporter proteins and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses also can be used in diagnostic methods, such detection and imaging of tumors. The viruses also can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including as anti-tumor agents.Type: ApplicationFiled: June 13, 2008Publication date: May 7, 2009Inventors: Nanhai Chen, Aladar A. Szalay, Yong A. Yu, Qian Zhang, Yuman Fong
-
Patent number: 7527786Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.Type: GrantFiled: August 21, 2002Date of Patent: May 5, 2009Assignees: The Regents of the University of California, Agensys, Inc.Inventors: Robert E Reiter, Owen N Witte
-
Patent number: 7524498Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.Type: GrantFiled: September 12, 2007Date of Patent: April 28, 2009Assignees: CureTech Ltd., Mor-Research Application Ltd.Inventors: Britta Hardy, Steven Tarran Jones, Leah Klapper
-
Publication number: 20090104115Abstract: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: ApplicationFiled: October 2, 2008Publication date: April 23, 2009Inventors: David S.F. Young, Helen P. Findlay, Susan E. Hahn, Lisa M. Cechetto
-
Patent number: 7521047Abstract: The present invention relates to polypeptide compositions which bind to cell surface epitopes and, in multivalent forms, cause or lead to the killing of cells including lymphoid tumor cells, and in the case of monovalent forms, cause immunosuppression or otherwise inhibit activation of lymphocytes. The invention further relates to nucleic acids encoding the polypeptides, methods for the production of the polypeptides, methods for killing cells, methods for immunosuppressing a patient, pharmaceutical, diagnostic and multivalent compositions and kits comprising the polypeptides and uses of the polypeptides.Type: GrantFiled: November 15, 2001Date of Patent: April 21, 2009Assignees: GPC Biotech AG, Morphosys AGInventors: Zoltan Nagy, Christoph Brunner, Michael Tesar, Elisabeth Thomassen-Wolf, Robert Rauchenberger
-
Patent number: 7521542Abstract: The present invention relates to humanized Fc?RIIB antibodies, fragments, and variants thereof that bind human Fc?RIIB with a greater affinity than said antibody binds Fc?RIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express Fc?RIIB.Type: GrantFiled: May 10, 2005Date of Patent: April 21, 2009Assignee: MacroGenics, Inc.Inventors: Leslie S. Johnson, Ling Huang
-
Patent number: 7521056Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization and docking domain attached to a first precursor, and a second monomer comprising an anchoring domain attached to a second precursor. The first and second precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc.Type: GrantFiled: March 28, 2006Date of Patent: April 21, 2009Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Patent number: 7521053Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.Type: GrantFiled: October 10, 2002Date of Patent: April 21, 2009Assignees: Amgen Inc., Medarex, Inc.Inventor: Jonathan Daniel Oliner
-
Publication number: 20090098045Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMABs of the instant invention.Type: ApplicationFiled: November 19, 2008Publication date: April 16, 2009Inventors: David S. F. Young, Susan E. Hahn, Helen P. Findlay, Alison L. Ferry
-
Patent number: 7517964Abstract: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.Type: GrantFiled: May 8, 2007Date of Patent: April 14, 2009Assignee: Immunomedics, Inc.Inventors: Serengulam Govindan, Zhengxing Qu, Hans Hansen, Davd M. Goldenberg
-
Patent number: 7517967Abstract: The present invention relates to monoclonal antibody 1A7. This is an anti-idiotype produced by immunizing with an antibody specific for ganglioside GD2, and identifying a hybridoma secreting antibody with immunogenic potential in a multi-step screening process. Also disclosed are polynucleotide and polypeptide derivatives based on 1A7, including single chain variable region molecules and fusion proteins, and various pharmaceutical compositions. When administered to an individual, the 1A7 antibody overcomes immune tolerance and induces an immune response against GD2, which comprises a combination of anti-GD2 antibody and GD2-specific T cells. The invention further provides methods for treating a disease associated with altered GD2 expression, particularly melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell carcinoma. Patients who are in remission as a result of traditional modes of cancer therapy may be treat with a composition of this invention in hopes of reducing the risk of recurrence.Type: GrantFiled: March 23, 2005Date of Patent: April 14, 2009Assignee: University of Kentucky Research FoundationInventors: Malaya Chatterjee, Kenneth A. Foon, Sunil K. Chatterjee
-
Patent number: 7507724Abstract: This invention provides a composition comprising an effective amount of (1-3)-?-glucan derived from barley capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject.Type: GrantFiled: July 16, 2003Date of Patent: March 24, 2009Assignee: Sloan-Kettering Institute for Cancer ResearchInventor: Nai-Kong V. Cheung
-
Patent number: 7507537Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB) or derivatives thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMABs of the instant invention.Type: GrantFiled: November 3, 2006Date of Patent: March 24, 2009Assignee: Hoffmann-La Roche Inc.Inventors: David S. F. Young, Susan E. Hahn, Helen P. Findlay
-
Publication number: 20090074659Abstract: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: ApplicationFiled: March 20, 2008Publication date: March 19, 2009Inventors: David S. F. Young, Susan E. Hahn, Lisa M. Cechetto
-
Publication number: 20090074662Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: ApplicationFiled: November 19, 2008Publication date: March 19, 2009Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Daad Sayegh
-
Publication number: 20090074789Abstract: The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, particularly ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation, and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against the bioactive lipid, sphingosine-1-phosphate, and its variants, which moieties are capable of decreasing the effective concentration of bioactive lipid being targeted. In one embodiment, the immune-derived moiety is a humanized monoclonal antibody that is reactive against sphingosine-1-phosphate.Type: ApplicationFiled: October 26, 2007Publication date: March 19, 2009Inventors: Roger A. SABBADINI, William A. GARLAND, Glenn L. STOLLER
-
Publication number: 20090068099Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: ApplicationFiled: August 22, 2008Publication date: March 12, 2009Inventors: David S.F. Young, Helen P. Findlay, Susan E. Hahn
-
Publication number: 20090068144Abstract: The present invention provides a compound selected from compounds of formula I as ligand binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy. Compounds of formula (I) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer's Disease, injury from ischemic events, heart valvular degenerative disease Moreover, compounds of formula (I) can be used to decrease the side effects from cytotoxic cancer agents and to treat viral infections.Type: ApplicationFiled: March 17, 2006Publication date: March 12, 2009Inventors: Lutz Weber, Vladimir Khazak, Gunther Ross, Cotic Kalinski, Chritoph Burdack
-
Publication number: 20090068141Abstract: The invention provides a simple, cost-effective method of preparing a composition comprising natural killer (NK) cells useful for administering to a human. The method comprises (i) depleting CD3+ cells from a population of PBMCs comprising NK cells, and (ii) co-culturing cells from (i) with irradiated PBMCs that are autologous to the NK cells. Further provided by the invention are the compositions prepared thereby and methods of treating or preventing a disease or immunodeficiency in a host.Type: ApplicationFiled: September 5, 2008Publication date: March 12, 2009Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Maria R. Parkhurst, Steven A. Rosenberg
-
Patent number: 7501122Abstract: The present application describes methods for treating ErbB-expressing cancer with anti-ErbB2 antibody combinations.Type: GrantFiled: September 9, 2005Date of Patent: March 10, 2009Assignee: Genentech, Inc.Inventors: Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
-
Publication number: 20090060913Abstract: The present invention is directed to a combination therapy involving a type I anti-CD20 antibody and a type II anti-CD20 antibody for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type I anti-CD20 antibody and a type II anti-CD20 antibody. Another aspect of the invention is a kit comprising a type I anti-CD20 antibody and a type II anti-CD20 antibody. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type I anti-CD20 antibody and a type II anti-CD20 antibody.Type: ApplicationFiled: September 3, 2008Publication date: March 5, 2009Inventors: Thomas Friess, Christian Klein, Pablo Umana
-
Patent number: 7498029Abstract: The present invention relates to photosensitizer immunoconjugate compositions and combination therapies for use in cancer related photodynamic treatments and diagnostic methods. Photosensitizer immunoconjugates comprising a photosensitizer conjugated to a tumor-specific and/or tumoricidial antibody and processes for the preparation thereof are described. The use of photosensitizer immunoconjugates (PICs) offers improved photosensitizer delivery specificity for diagnostic and therapeutic applications. Combination therapies to co-localize activated photosensitizer compounds and tumoricidal antibodies in tumor tissues are also described.Type: GrantFiled: May 1, 2002Date of Patent: March 3, 2009Assignee: The General Hospital CorporationInventors: Tayyaba Hasan, Mark D. Savellano, Mihaela Skobe
-
Patent number: 7498142Abstract: A method of identifying a combination of antibodies with a combined improved anti tumor activity is provided. The method comprising identifying at least two anti RTK antibodies capable of inducing synergistic endocytosis of the RTK in a cell expressing the RTK, thereby identifying the combination of antibodies with the combined improved anti-tumor activity.Type: GrantFiled: January 31, 2006Date of Patent: March 3, 2009Assignee: Yeda Research and Development Co., Ltd.Inventors: Yosef Yarden, Michael Sela